Washington University School of Medicine in St. Louis is radically advancing immunotherapy treatments and personalized cancer therapies. PICI researcher Robert D. Schreiber, PhD, has championed the power of immunotherapy for more than 25 years. He translates basic research principles into clinical trials and drives new therapeutic approaches. Matthew Gubin, PhD, Parker Bridge Scholar, works in Schreiber’s lab researching tumor growth and rejection to improve responses to checkpoint blockade therapies. Together with PICI, they focus on T-cells and activating responses for more patients and more cancer types. Robert D. Schreiber, PhD | Investigator Matthew Gubin, PhD | Bridge Scholar Related Research Project Tumor Neoantigen Selection Alliance (TESLA) Research Focus Tumor Antigen Discovery: Targeting Cancer Announcement PICI Network Presenters at #KScelltherapy23 Our Impact 2022 Year in Review Announcement PICI Network Researchers to Present at #ASH22 Announcement PICI Network Researchers to Present at #SITC22 Announcement Dana-Farber and Gladstone Institutes Join PICI Network Announcement, Our Impact Parker Institute Researchers Featured at #CICON22 Announcement, Our Impact Latest Pancreatic Cancer Findings Highlighted